by Bioblast Editor | Aug 10, 2020 | Biosimilars updates
AVEO Oncology releases its Q2 FY2020 earnings report. AVEO reported data from its Ph I study of ficlatuzumab and cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC) demonstrated that the products have an acceptable safety profile and...
by Bioblast Editor | Apr 8, 2020 | Biosimilars updates
Pfizer announces the FDA has approved Braftovi® (encorafenib) in combination with Erbitux® (cetuximab) for the treatment of BRAF600E-mutant metastatic colorectal cancer after prior therapy.
by Bioblast Editor | Sep 18, 2018 | Biosimilars updates
Researchers release results of pre-clinical study of cetuximab candidate APZ001.
by Bioblast Editor | Jan 10, 2018 | Biosimilars updates
Amgen discloses at JP Morgan Healthcare Conference that it is in process development for a cetuximab biosimilar.
by Bioblast Editor | Jan 11, 2016 | Biosimilars updates
MabTech announces successful Chinese Ph III clinical trials for Sorrento’s “biosimilar/biobetter” cetuximab STI-001, and infliximab STI-002.
